Capricor Therapeutics
-

US FDA Rejects Capricor’s Duchenne Therapy Over Data Integrity Issues
The US FDA rejected Capricor Therapeutics’ deramiocel for Duchenne muscular dystrophy, citing severe data integrity issues and protocol violations.
-

Capricor Therapeutics Faces Class Action Investigation After FDA Data Concerns Trigger 64% Stock Collapse
Rosen Law Firm has launched an investigation into Capricor Therapeutics following a 64% stock plunge triggered by FDA staff concerns over its DMD therapy, deramiocel.
